Chronic Hepatitis c Clinical Trial
Official title:
Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection - a Prospective Observational Cohort Study
The purpose of this study is the evaluation of PAH in patients, who are treated with DAA medication for HCV infection.
Study category and Rationale: This study is without any use of medication or investigations
products, therefore this is a category A clinical trail.
Background and Rationale: Pulmonary arterial hypertension (PAH) is a chronic and progressive
disease leading to right heart failure and ultimately death in untreated patients. A variety
of systemic illnesses have been associated with PAH. Hepatitis C virus (HCV) infection is not
defined as a risk factor for PAH. However, compared to a control population higher pulmonary
artery pressures are described in patients with HCV. Some case reports indicate association
between HCV medication and PAH. Except of a few case reports, to date no clinical study about
evidence of PAH in patients with direct-acting-antiviral (DAA) medication for HCV infection
has been published.
Objective: The purpose of this study is the evaluation of PAH in patients, who are treated
with DAA medication for HCV infection.
Outcomes: The primary outcome of this study is the evaluation of pulmonary artery pressure
change using transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of
HCV before and after treatment with DAA medication. The secondary outcomes are the change in
left and right ventricular structure and function using TTE in patients with a new diagnosis
of HCV before and after treatment with DAA medication.
Study design: A single center prospective, observational cohort study. Inclusion / Exclusion
criteria: Inclusion criteria are evidence of HCV infection and age 18-90 years. Patients will
be excluded from the study, if there is an inability to provide informed consent and if there
are known for existing PAH.
Measurements and procedures: The patients will receive a TTE for the measurement of the
pulmonary artery pressure before, during (8 weeks after starting the medication) and 8 weeks
after completion of the HCV medication. The whole treatment period will take about 12 weeks.
Study Product / Intervention: The study will use a TTE for measurement of pulmonary artery
pressure. This non-invasive, fast investigation (total duration about 20 minutes) is used for
years in Cardiology and does not constitute a specific study product.
Number of Participants with Rationale:The study goal ist the înlusion of 50 participants with
a newly started DAA medication for HCV infection. Due to the lack of data, a power
calculation is not possible. However, if a higher number than 50 participants would be
necessary to show a significant rise in pulmonary pressure, a clinical significance is not
likely to be relevant.
Study Duration: The study inclusion is planned for 2 year.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
| Completed |
NCT03673696 -
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT02250001 -
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
|
N/A | |
| Completed |
NCT03088917 -
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
|
||
| Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
| Not yet recruiting |
NCT02865369 -
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
|
N/A | |
| Recruiting |
NCT02638233 -
Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy
|
Phase 4 | |
| Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
| Completed |
NCT02788682 -
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy
|
N/A | |
| Not yet recruiting |
NCT01949168 -
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
|
Phase 2 | |
| Completed |
NCT01439776 -
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
|
Phase 4 | |
| Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A | |
| Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A | |
| Completed |
NCT00968357 -
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
|
Phase 2 | |
| Terminated |
NCT00962936 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00575627 -
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
|
Phase 4 | |
| Recruiting |
NCT01178749 -
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
|
N/A | |
| Completed |
NCT00537407 -
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
|
Phase 2 | |
| Recruiting |
NCT00370617 -
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
|
Phase 4 | |
| Completed |
NCT01684787 -
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
|
Phase 4 |